Jeffrey M Jacobson

Summary

Affiliation: Beth Israel Medical Center
Country: USA

Publications

  1. ncbi request reprint Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068
    Jeffrey M Jacobson
    Beth Israel Medical Center and Albert Einstein College of Medicine, New York, NY 10003, USA
    J Infect Dis 194:623-32. 2006
  2. ncbi request reprint Immune-based therapies: an adjunct to antiretroviral treatment
    Jeffrey M Jacobson
    Beth Israel Medical Center, Albert Einstein College of Medicine, New York, New York 10003, USA
    Curr HIV/AIDS Rep 2:90-7. 2005
  3. ncbi request reprint Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection
    Jeffrey M Jacobson
    Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
    J Infect Dis 188:1804-14. 2003
  4. pmc Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542
    Jeffrey M Jacobson
    Mount Sinai Medical Center, New York, New York 10029 Progenics Pharmaceuticals, Inc, Tarrytown, New York 10591, USA
    Antimicrob Agents Chemother 48:423-9. 2004
  5. doi request reprint Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
    Christopher J Bruno
    Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
    J Antimicrob Chemother 65:1839-41. 2010
  6. pmc The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
    Jeffrey M Jacobson
    Division of Infectious Diseased and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA Division of Infectious Diseases, University of Colorado, Denver, CO Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA Profectus BioSciences, Inc, Tarrytown, NY Department of Immunology and Microbiology, Rush University School of Medicine, Chicago, IL Department of Neurology, Washington University School of Medicine, St Louis, MO HIV AIDS Division, University of California, San Francisco, CA Social and Scientific Systems, Inc, Silver Springs, MD Division of AIDS, NIAID, Bethesda, MD Frontier Science, Amherst, NY and Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
    J Acquir Immune Defic Syndr 71:163-71. 2016
  7. pmc CCR5 monoclonal antibodies for HIV-1 therapy
    William C Olson
    Progenics Pharmaceuticals Inc, Tarrytown, NY 10591, USA
    Curr Opin HIV AIDS 4:104-11. 2009
  8. ncbi request reprint Effects of highly active antiretroviral therapy on HIV-1-associated oral complications
    Zahida Parveen
    Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Curr HIV Res 5:281-92. 2007
  9. ncbi request reprint Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV
    Rosalind G Hoffman
    Mount Sinai Medical Center, New York, New York 10029, USA
    Psychosomatics 44:417-20. 2003
  10. pmc Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA Division of Hematology and Chronic Viral Illness Service, McGill University, Montreal, Quebec, Canada Department of Epidemiology and Biostatistics, Drexel University College of Medicine, Philadelphia, PA Argostherapeutics, Durham, NC Division of Infectious Diseases, the Ottawa Hospital and the University of Ottawa, Ottawa, CA Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA Department of Medicine, Albert Einstein College of Medicine, New York, NY Clinique Medicale du Quartier Latin, Montreal, Quebec, Canada Duke University Medical Center, Durham, NC UNC HIV Cure Center and Departments of Medicine, Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC Clinique Medicale l Actuel, Montreal, Quebec, Canada and Frontier Science, Amherst, NY
    J Acquir Immune Defic Syndr 72:31-8. 2016

Detail Information

Publications21

  1. ncbi request reprint Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068
    Jeffrey M Jacobson
    Beth Israel Medical Center and Albert Einstein College of Medicine, New York, NY 10003, USA
    J Infect Dis 194:623-32. 2006
    ....
  2. ncbi request reprint Immune-based therapies: an adjunct to antiretroviral treatment
    Jeffrey M Jacobson
    Beth Israel Medical Center, Albert Einstein College of Medicine, New York, New York 10003, USA
    Curr HIV/AIDS Rep 2:90-7. 2005
    ..Strategies to reduce the immunopathogenic consequences of HIV infection with immunomodulating therapies are conceivable. Ultimately, eradication of the infection will require methods to target the latent memory T-cell reservoir of virus...
  3. ncbi request reprint Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection
    Jeffrey M Jacobson
    Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
    J Infect Dis 188:1804-14. 2003
    ..Studies have reported that plasma human immunodeficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)...
  4. pmc Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542
    Jeffrey M Jacobson
    Mount Sinai Medical Center, New York, New York 10029 Progenics Pharmaceuticals, Inc, Tarrytown, New York 10591, USA
    Antimicrob Agents Chemother 48:423-9. 2004
    ..The findings support continued development of PRO 542 for salvage therapy of advanced HIV-1 disease...
  5. doi request reprint Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
    Christopher J Bruno
    Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
    J Antimicrob Chemother 65:1839-41. 2010
    ..Its unique mode of action reduces the risk of cross-resistance with currently available antiretroviral agents, with the potential to expand the choices available to treat drug-resistant HIV-1...
  6. pmc The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
    Jeffrey M Jacobson
    Division of Infectious Diseased and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA Division of Infectious Diseases, University of Colorado, Denver, CO Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA Profectus BioSciences, Inc, Tarrytown, NY Department of Immunology and Microbiology, Rush University School of Medicine, Chicago, IL Department of Neurology, Washington University School of Medicine, St Louis, MO HIV AIDS Division, University of California, San Francisco, CA Social and Scientific Systems, Inc, Silver Springs, MD Division of AIDS, NIAID, Bethesda, MD Frontier Science, Amherst, NY and Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
    J Acquir Immune Defic Syndr 71:163-71. 2016
    ..The Profectus Biosciences multiantigen (MAG) HIV-1 DNA vaccine encodes HIV-1 Gag/Pol, Nef/Tat/Vif, and Envelope, and interleukin-12 (IL-12) and is delivered by electroporation combined with intramuscular injection (IM-EP)...
  7. pmc CCR5 monoclonal antibodies for HIV-1 therapy
    William C Olson
    Progenics Pharmaceuticals Inc, Tarrytown, NY 10591, USA
    Curr Opin HIV AIDS 4:104-11. 2009
    ..Two CCR5 mAbs have entered clinical testing and have successfully completed proof-of-concept studies in HIV-infected individuals, providing initial information on the potential therapeutic utility of these agents...
  8. ncbi request reprint Effects of highly active antiretroviral therapy on HIV-1-associated oral complications
    Zahida Parveen
    Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Curr HIV Res 5:281-92. 2007
    ..Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented...
  9. ncbi request reprint Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV
    Rosalind G Hoffman
    Mount Sinai Medical Center, New York, New York 10029, USA
    Psychosomatics 44:417-20. 2003
  10. pmc Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA Division of Hematology and Chronic Viral Illness Service, McGill University, Montreal, Quebec, Canada Department of Epidemiology and Biostatistics, Drexel University College of Medicine, Philadelphia, PA Argostherapeutics, Durham, NC Division of Infectious Diseases, the Ottawa Hospital and the University of Ottawa, Ottawa, CA Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA Department of Medicine, Albert Einstein College of Medicine, New York, NY Clinique Medicale du Quartier Latin, Montreal, Quebec, Canada Duke University Medical Center, Durham, NC UNC HIV Cure Center and Departments of Medicine, Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC Clinique Medicale l Actuel, Montreal, Quebec, Canada and Frontier Science, Amherst, NY
    J Acquir Immune Defic Syndr 72:31-8. 2016
    ..AGS-004 amplifies translation-competent RNA molecules encoding for Gag, Rev, Vpr, and Nef from the patient's autologous virus and loads them into dendritic cells...
  11. pmc A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA AIDS Clinical Trials Group, Statistical and Data Analysis Center, Harvard University School of Public Health, Boston, MA Vaccine and Gene Therapy Institute, Port Saint Lucie, FL Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI Department of Immunology Microbiology, Rush University School of Medicine, Chicago, IL Division of Hematology and Chronic Viral Illness Service, McGill University Health Centre, Montreal, CA Division of Infectious Diseases, Department of Medicine, University of California, San Diego, School of Medicine, San Diego, CA Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN Social and Scienti x fb01 c Systems, Inc, Silver Springs, MD Frontier Sciences, Buffalo, NY and Division of AIDS, NIAID, Bethesda, MD
    J Acquir Immune Defic Syndr 66:399-406. 2014
    ..Palifermin (keratinocyte growth factor), by providing support to the thymic epithelium, promotes lymphopoiesis in animal models of bone marrow transplantation and graft-versus-host disease...
  12. pmc HIV- and AIDS-related knowledge, awareness, and practices in Madagascar
    Nicole M Lanouette
    Mount Sinai School of Medicine, New York, NY, USA
    Am J Public Health 93:917-9. 2003
  13. ncbi request reprint The prevalence of distress in persons with human immunodeficiency virus infection
    MaryAnn Cohen
    AIDS Center, Box 1009, Mount Sinai Medical Center, One Gustave L Levy Place, New York, NY 10029, USA
    Psychosomatics 43:10-5. 2002
    ..The HADS and the Distress Thermometer showed a good correlation with each other (P < 0.0005), and these questionnaires can provide a simple and efficient method for rapid screening in an HIV clinic setting...
  14. ncbi request reprint Evaluation of cellular immune responses in subjects chronically infected with HIV type 1
    Tong Ming Fu
    Merck Research Laboratories, West Point, PA 19486, USA
    AIDS Res Hum Retroviruses 23:67-76. 2007
    ..Our findings suggest that the high levels of ELISpot responses in chronically infected subjects were reflective of their persistent viral infection...
  15. pmc Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127
    Marion G Peters
    University of California, San Francisco, San Francisco, CA, USA
    Hepatology 44:1110-6. 2006
    ..In conclusion, over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA. Both drugs are safe and efficacious for patients coinfected with HBV and HIV...
  16. ncbi request reprint A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102
    Keith Henry
    HIV Program, Hennepin County Medical Center and the University of Minnesota, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 42:140-8. 2006
    ..By boosting CD4 T-cell counts, interleukin 2 (IL-2) could safely prolong the duration of treatment interruption (TI) in a CD4-driven strategy...
  17. ncbi request reprint A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)
    Robert S Wallis
    The University Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
    J Acquir Immune Defic Syndr 32:281-6. 2003
    ..The potential role of corticosteroids as tools to examine this question will be limited by concerns regarding their toxicity; however, further studies of other agents to limit cellular activation in AIDS are warranted...
  18. ncbi request reprint A reporting tool for real-time assessment of study data availability
    Ronald J Bosch
    Clin Trials 1:339-40. 2004
    ..A simple framework for assessing and reporting data availability in an ongoing clinical trial is described. Protocol requirements, visit schedules and data availability are combined into a simple report to track the progress of a study...
  19. ncbi request reprint Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Georgia, USA
    AIDS 19:1607-15. 2005
    ..To evaluate the pharmacodynamics and safety of escalating doses of amdoxovir (DAPD) monotherapy administered to treatment-naive and experienced HIV-1-infected patients over 15 days...
  20. ncbi request reprint Actin integrity is indispensable for CD95/Fas-induced apoptosis of HIV-specific CD8+ T cells
    Constantinos Petrovas
    Department of Microbiology and Immunology, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Drexel University, 2900 Queen Lane, Philadelphia, PA 19129, USA
    Apoptosis 12:2175-86. 2007
    ....
  21. ncbi request reprint Trials that matter: CD4+ T-lymphocyte count-guided interruption of antiretroviral therapy in HIV-infected patients
    Jeffrey M Jacobson
    Ann Intern Med 146:682-3. 2007